The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure

19999,028 citationsJournal Articlebronze Open Access

Authors

Bertram Pitt · University of Michigan–Ann Arbor

Faı̈ez Zannad · Centre d’Investigation Clinique Innovation Technologique de Nancy

Willem J. Remme

Robert Cody · University of Michigan–Ann Arbor

A Castaigne

A.J. Pérez Pérez

Jolie Palensky · Statistics Collaborative

Janet Wittes · Statistics Collaborative

Abstract

Blockade of aldosterone receptors by spironolactone, in addition to standard therapy, substantially reduces the risk of both morbidity and death among patients with severe heart failure.

Topics & Keywords

Hormonal Regulation and Hypertension Heart Failure Treatment and Management Blood Pressure and Hypertension Studies

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: New England Journal of Medicine

Volume 341, Issue 10, pp. 709-717

DOI: 10.1056/nejm199909023411001

Field-Weighted Citation Impact: 168.71